Claros Diagnostics
Founded Year
2004Stage
Series B | DeadTotal Raised
$14.8MLast Raised
$4M
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Claros Diagnostics Patents
Claros Diagnostics has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/11/2010 | 9/27/2011 | Grant |
Application Date | 5/11/2010 |
|---|---|
Grant Date | 9/27/2011 |
Title | |
Related Topics | |
Status | Grant |
Latest Claros Diagnostics News
Aug 10, 2011
August 10th, 2011 Wouter Stomp Diagnostics , Exclusive Last week we reported on the success of the mChip lab-on-a-chip HIV and syphilis test in its first field trial. For some further information, we got in touch with Samuel K. Sia, associate professor at the department of biomedical engineering at Columbia University, who was one of the leading researchers in this study. His lab focuses on using microfluidics for global health diagnostics and for 3D tissue biology and he is one of the founders of Claros Diagnostics, the company responsible for commercializing the mChip diagnostic platform. 1. How long did it take you to develop this chip and what difficulties did you encounter? We started the work in 2002 when Vincent Linder and I were postdocs in George Whitesides’ lab at Harvard. Taking a proof of concept, even if one that already works in principle, to something robust in the field has required a large part of clever engineering and development, much of it at Claros Diagnostics. 2. Are there any further/larger trials planned with the current device? We are always planning more trials, both with the version published in the most recent study as well as other versions. 3. How long do you expect it will take until this or similar devices will be used in practice in developing countries? If funding and resources were not constraining, we think we can get significant adoption within 2 years. 4. The reported sensitivity and specificity are very high. Could it also have benefits in the Western world? Yes. Claros Diagnostics has developed a prostate cancer monitoring test that can be used in portable settings. This version gained the CE Mark in 2010 (i.e. approval from European Union). 5. In what other diseases is the mChip applicable, any criteria a disease needs to meet? Will future versions be able to give quantitative results as well? The Claros version already provides quantitative results, so that is an ability this technology can already accomplish. We are limited to diseases with validated protein markers, but that includes many conditions, including infectious diseases, cancer, and many other conditions. In addition to this interview, here are two videos about the lab-on-a-chip technology:
Claros Diagnostics Frequently Asked Questions (FAQ)
When was Claros Diagnostics founded?
Claros Diagnostics was founded in 2004.
Where is Claros Diagnostics's headquarters?
Claros Diagnostics's headquarters is located at 4 Constitution Way, Woburn.
What is Claros Diagnostics's latest funding round?
Claros Diagnostics's latest funding round is Series B.
How much did Claros Diagnostics raise?
Claros Diagnostics raised a total of $14.8M.
Who are the investors of Claros Diagnostics?
Investors of Claros Diagnostics include BioVentures Investors, Commons Capital, Accelerated Technologies Partners, Oxford Bioscience Partners and Bill & Melinda Gates Foundation.
Who are Claros Diagnostics's competitors?
Competitors of Claros Diagnostics include MedShape, Respicardia, Neotract, IntraOp Medical, GRAFTcath and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Claros Diagnostics to Competitors
Primaeva Medical is an early stage medical device company developing a skin tightening and rejuvenation dermatological device
GRAFTcath is a medical device company developing vascular access products for hemodialysis.
ExploraMed is a medical technology incubation company dedicated to the identification, creation and development of medical device solutions. ExploraMed creates ideas in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development.
BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.
Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.
The Diamorph group engages in development, manufacturing and sales of high performance products in the areas of fire protection, rail, pumps and compressors, marine and ceramic rollers and the customers can be found in more than 60 countries.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
